https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/731645 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly Hanmi signage Credit: Hanmi Pharmaceutical Co. Ltd. http://www.bioworld.com/articles/731525 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731525-cancer-specter-looming-abtect-effect-in-uc-wallops-abivax Person holding stomach in pain http://www.bioworld.com/articles/731582 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731582-ax-2911-shows-in-vivo-activity-by-correcting-pnpla3-in-mash Liver illustration Credit: Georgia State University http://www.bioworld.com/articles/731581 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731581-prd-001-shows-synergy-with-rezdiffra-for-treating-mash Liver disease http://www.bioworld.com/articles/731576 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731576-easl-spotlight-tune-401-advances-epigenetic-silencing-in-hbv Hepatitis B virus rendering Hepatitis B virus. Credit: NIAID, CC BY 2.0. Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of cases. Antibiotics that normally combat diarrhea are not recommended for STEC infections and patients are usually treated only for symptomatology. Now, French researchers from Eligo Bioscience SA and their collaborators have published a paper on a CRISPR-based antimicrobial approach, EB-003.]]> http://www.bioworld.com/articles/731575 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731575-crispr-based-approach-fights-pathogenic-eme-coli-em Illustration of E. coli with window showing DNA E.coli. Credit: Thom Leach. License: CC by SA http://www.bioworld.com/articles/731459 Mon, 01 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731459-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly Hanmi signage Credit: Hanmi Pharmaceutical Co. Ltd. http://www.bioworld.com/articles/731558 Mon, 01 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731558-plt-012-shows-efficacy-across-different-mash-models 3D illustration of liver and photomicrograph showing triglyceride fat accumulated in liver cells. An estimated 444 million people worldwide are living with NASH/MASH. http://www.bioworld.com/articles/731553 Mon, 01 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731553-easl-2026-emerging-liver-disease-targets-to-watch Liver over digital lens background http://www.bioworld.com/articles/731491 Fri, 29 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731491-pancreatic-lesions-show-cancer-traits-but-lack-stromal-support Immunofluorescence image of human donor pancreas with a precursor lesion lined by epithelial cells surrounded by fibroblasts. Immunofluorescence image of human donor pancreas with a precursor lesion lined by epithelial cells surrounded by fibroblasts. Credit: Pasca Lab http://www.bioworld.com/articles/731472 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731472-easl-2026-rebuilding-the-liver-from-organoids-to-engineered-ducts Liver illustration http://www.bioworld.com/articles/731364 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731364-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong. http://www.bioworld.com/articles/731101 Thu, 14 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731101-epiriums-15-pgdh-inhibitor-ibd-candidates-improve-disease-outcomes-in-models Intestine http://www.bioworld.com/articles/731063 Wed, 13 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/731063-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong. http://www.bioworld.com/articles/730995 Mon, 11 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730995-mabwells-9mw5211-gains-ind-clearance-for-ibd Hands holding holographic intestine http://www.bioworld.com/articles/730907 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730907-kymeras-irf5-degrader-shows-potential-in-ibd-treatment Art concept for inflammation in the intestines http://www.bioworld.com/articles/730688 Wed, 29 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730688-enterobiotix-raises-257m-for-phase-iib-of-microbiome-pill-in-ibs British pound symbol http://www.bioworld.com/articles/730743 Wed, 29 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730743-montais-mtai-1025-demonstrates-efficacy-in-ulcerative-colitis Illustration of intestines with inflammation
“If we could figure out what those signals were, we could synthetically drive these factors locally in an implant to control its growth ourselves,” first author Amy Stoddard told BioWorld. Stoddard is a postdoctoral researcher at the Wyss Institute.]]> http://www.bioworld.com/articles/730717 Tue, 28 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730717-novel-method-boosts-organ-growth-after-transplantation Pink and blue neon arrows demonstrating acceleration http://www.bioworld.com/articles/730557 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730557-elpisciences-bispecific-antibody-es-302-reduces-disease-activity-in-ibd-model Illustration of intestinal track http://www.bioworld.com/articles/730574 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions http://www.bioworld.com/articles/730407 Fri, 17 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions http://www.bioworld.com/articles/730360 Tue, 14 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730360-mayinglong-pharmaceutical-presents-new-5-ht4-receptor-agonists http://www.bioworld.com/articles/730359 Tue, 14 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730359-hubei-bio-pharmaceutical-industrial-technological-institute-divulges-new-vav1-degraders http://www.bioworld.com/articles/730280 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730280-spyres-spy-001-induces-better-outcomes-in-ulcerative-colitis Ulcerative colitis http://www.bioworld.com/articles/730325 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730325-glp-1r-drug-response-tied-to-variants-in-target-genes Illustration of the human body next to a DNA double helix http://www.bioworld.com/articles/730262 Fri, 10 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730262-tipe2-silencing-attenuates-colitis Gastrointestinal system http://www.bioworld.com/articles/730238 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730238-proqr-therapeutics-expands-early-stage-pipeline RNA strand http://www.bioworld.com/articles/730087 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730087-korea-roundup-alteogen-celltrion-lead-biotech-deals Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left) Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left). http://www.bioworld.com/articles/729966 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729966-us-fda-says-no-again-to-vandas-tradipitant-in-gastroparesis